Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update

October 27, 2022 |

1 min read

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2022 financial results after market close on Thursday, November 3, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed product and pipeline of potential products, visit www.rigel.com.  

Contacts for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media: 
David Rosen 
Argot Partners 
212.600.1902 
david.rosen@argotpartners.com 